Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

B. Lowenberg, J. Beck, C. Graux, W van Putten, H.C. Schouten, L.F. Verdonck, A Ferrant, P. Sonneveld, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, B.J. Biemond, E. Vellenga, D. Breems, H. de Muijnck, R. Schaafsma, G. Verhoef, H. Dohner, A. Gratwohl, T. Pabst, G.J. OssenkoppeleJ. Maertens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2586-2591
Issue number13
Publication statusPublished - 2010

Cite this